Abstract
Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Current Neuropharmacology
Title: Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Volume: 8 Issue: 2
Author(s): Alberto Spalice, Pasquale Parisi, Laura Papetti, Francesco Nicita, Fabiana Ursitti, Francesca Del Balzo, Enrico Properzi, Alberto Verrotti, Martino Ruggieri and Paola Iannetti
Affiliation:
Keywords: Demyelinating disease, pediatric multiple sclerosis, ADEM, immune-mediate polyradiculoneuropathies, disease-modifying therapies, immunomodulatory therapy
Abstract: Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.
Export Options
About this article
Cite this article as:
Spalice Alberto, Parisi Pasquale, Papetti Laura, Nicita Francesco, Ursitti Fabiana, Del Balzo Francesca, Properzi Enrico, Verrotti Alberto, Ruggieri Martino and Iannetti Paola, Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update, Current Neuropharmacology 2010; 8 (2) . https://dx.doi.org/10.2174/157015910791233141
DOI https://dx.doi.org/10.2174/157015910791233141 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry The Role of NPY and Ghrelin in Anorexia Nervosa
Current Pharmaceutical Design Neurotoxicity of Insecticides
Current Medicinal Chemistry Fatal Disseminated Toxoplasmosis During Primary HIV Infection
Current HIV Research Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology New Agents to Treat Life-Threatening Fungal Infections
Current Topics in Medicinal Chemistry Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design Analgesic and Anti-Inflammatory Activities of Extracts and Fatty Acids from Celtis australis L
The Natural Products Journal Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy Diuretics in the Treatment of Elderly Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Relevance of Neuropeptide Y (NPY) in Psychiatry
Current Topics in Medicinal Chemistry Opioids and Mechanical Ventilation
Current Drug Targets Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Understanding the Cardiovascular Actions of Soy Isoflavones: Potential Novel Targets for Antihypertensive Drug Development
Cardiovascular & Hematological Disorders-Drug Targets Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Cycloaddition Methodology: A Useful Entry Towards Biologically Active Heterocycles
Current Organic Chemistry